BRPI0910901A2 - composição farmacêutica com bisfosfonato - Google Patents
composição farmacêutica com bisfosfonatoInfo
- Publication number
- BRPI0910901A2 BRPI0910901A2 BRPI0910901A BRPI0910901A BRPI0910901A2 BR PI0910901 A2 BRPI0910901 A2 BR PI0910901A2 BR PI0910901 A BRPI0910901 A BR PI0910901A BR PI0910901 A BRPI0910901 A BR PI0910901A BR PI0910901 A2 BRPI0910901 A2 BR PI0910901A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- bisphosphonate
- bisphosphonate pharmaceutical
- composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08154114 | 2008-04-04 | ||
PCT/EP2009/053965 WO2009121935A2 (en) | 2008-04-04 | 2009-04-02 | Pharmaceutical composition with bisphosphonate |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0910901A2 true BRPI0910901A2 (pt) | 2015-09-29 |
Family
ID=40149846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0910901A BRPI0910901A2 (pt) | 2008-04-04 | 2009-04-02 | composição farmacêutica com bisfosfonato |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110034418A1 (pt) |
EP (1) | EP2273980A2 (pt) |
JP (1) | JP2011516455A (pt) |
KR (1) | KR20110005837A (pt) |
CN (1) | CN102046152A (pt) |
AU (1) | AU2009232033A1 (pt) |
BR (1) | BRPI0910901A2 (pt) |
CA (1) | CA2720418A1 (pt) |
EA (1) | EA201001578A1 (pt) |
MX (1) | MX2010010943A (pt) |
WO (1) | WO2009121935A2 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2078052B1 (en) * | 2006-10-31 | 2010-07-28 | Surmodics Pharmaceuticals, Inc. | Spheronized polymer particles |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
PT2459176T (pt) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Método de cristalização e biodisponibilidade |
CN103313702A (zh) * | 2010-06-30 | 2013-09-18 | 赢创有限公司 | 用于热不稳定及其它的生物活性剂的植入物的制备方法和由该方法制备的植入物 |
IT1401882B1 (it) * | 2010-10-01 | 2013-08-28 | Rosa De | Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori. |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
GB201200868D0 (en) * | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
JO3394B1 (ar) * | 2014-07-04 | 2019-10-20 | Osteo Pharma B V | تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام |
JP6563415B2 (ja) * | 2014-11-05 | 2019-08-21 | 日本酢ビ・ポバール株式会社 | フィルムコーティング組成物並びに経口固形製剤及びその製造方法 |
KR20170083613A (ko) * | 2014-11-14 | 2017-07-18 | 난양 테크놀러지컬 유니버시티 | 생체흡수성 마그네슘 복합체 |
WO2016081281A1 (en) * | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
ES2546566B2 (es) * | 2015-07-23 | 2016-09-14 | Universidade De Santiago De Compostela | Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos |
KR102564469B1 (ko) | 2016-04-14 | 2023-08-08 | 삼성전자주식회사 | 배터리 보호 방법 및 장치 |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
EP3573747A4 (en) * | 2017-01-23 | 2020-12-30 | Savior Lifetec Corporation | PREPARATION OF MICROPARTICLES OF AN ACTIVE SUBSTANCE |
JP7357885B2 (ja) * | 2019-05-30 | 2023-10-10 | シァメン・ユニヴァーシティ | リセドロン酸亜鉛マイクロ/ナノアジュバントの作製及びワクチンアジュバントとしてのその使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3626058A1 (de) * | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
EP0275821B1 (de) * | 1986-11-21 | 1992-02-26 | Ciba-Geigy Ag | Neue substituierte Alkandiphosphonsäuren |
GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
CA2497353C (en) * | 2002-09-16 | 2012-08-28 | Novartis Ag | Method for preventing or reducing secondary fractures after hip fracture |
AR063121A1 (es) * | 2006-10-05 | 2008-12-30 | Novartis Ag | Composicion farmaceutica |
EA201000860A1 (ru) * | 2007-11-30 | 2010-12-30 | Новартис Аг | С-с-алкилимидазолбисфосфонаты |
-
2009
- 2009-04-02 WO PCT/EP2009/053965 patent/WO2009121935A2/en active Application Filing
- 2009-04-02 CA CA2720418A patent/CA2720418A1/en not_active Abandoned
- 2009-04-02 EA EA201001578A patent/EA201001578A1/ru unknown
- 2009-04-02 KR KR1020107024706A patent/KR20110005837A/ko not_active Application Discontinuation
- 2009-04-02 BR BRPI0910901A patent/BRPI0910901A2/pt not_active IP Right Cessation
- 2009-04-02 MX MX2010010943A patent/MX2010010943A/es not_active Application Discontinuation
- 2009-04-02 AU AU2009232033A patent/AU2009232033A1/en not_active Abandoned
- 2009-04-02 JP JP2011502387A patent/JP2011516455A/ja active Pending
- 2009-04-02 CN CN2009801204817A patent/CN102046152A/zh active Pending
- 2009-04-02 EP EP09729083A patent/EP2273980A2/en not_active Withdrawn
- 2009-04-02 US US12/935,402 patent/US20110034418A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20110005837A (ko) | 2011-01-19 |
US20110034418A1 (en) | 2011-02-10 |
CN102046152A (zh) | 2011-05-04 |
EP2273980A2 (en) | 2011-01-19 |
MX2010010943A (es) | 2012-09-28 |
CA2720418A1 (en) | 2009-10-08 |
WO2009121935A3 (en) | 2010-06-03 |
JP2011516455A (ja) | 2011-05-26 |
AU2009232033A1 (en) | 2009-10-08 |
WO2009121935A2 (en) | 2009-10-08 |
EA201001578A1 (ru) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
LTPA2018005I1 (lt) | Farmacinė kompozicija | |
BRPI0910901A2 (pt) | composição farmacêutica com bisfosfonato | |
SMT201600259B (it) | Composizioni farmaceutiche antibatteriche | |
SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
DE602008002756D1 (de) | Bauzusammensetzung | |
RU2493831C3 (ru) | Фармацевтические композиции | |
DK3097925T3 (da) | Farmaceutisk sammensætning | |
DK2273984T3 (da) | Lipidsammensætning | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
BRPI1004940A2 (pt) | composição farmacêutica | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
BRPI0917231A2 (pt) | composição | |
BRPI1015939A2 (pt) | composição farmacêutica | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0921654A2 (pt) | formulação farmacêutica | |
DK3300729T3 (da) | Terapeutiske sammensætninger indeholdende macitentan | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0820198A2 (pt) | composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |